Go to
current issue
-
Adoption of organ-on-chip platforms by the pharmaceutical industry. Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-10-13 Paul Vulto,Jos Joore
-
CRISPR technologies are going to need a bigger toolbox Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-10-12
Feng Zhang discusses the expanding gene-editing toolkit, the need for better delivery systems and the reprogrammable biological technologies that remain to be discovered.
-
FDA new drug approvals in Q3 2021 Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-10-12
Discover the world’s best science and medicine | Nature.com
-
mRNA flu shots move into trials Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-10-11
COVID-19 provided an opportunity to show that mRNA vaccines can work. Now, drug companies are racing to apply the technology platform for influenza.
-
Engineering living therapeutics with synthetic biology Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-10-06 Andres Cubillos-Ruiz, Tingxi Guo, Anna Sokolovska, Paul F. Miller, James J. Collins, Timothy K. Lu, Jose M. Lora
The steadfast advance of the synthetic biology field has enabled scientists to use genetically engineered cells, instead of small molecules or biologics, as the basis for the development of novel therapeutics. Cells endowed with synthetic gene circuits can control the localization, timing and dosage of therapeutic activities in response to specific disease biomarkers and thus represent a powerful new
-
Understanding PI3K inhibitor mechanism of action Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-10-05
Discover the world’s best science and medicine | Nature.com
-
A safe and effective DNA hypomethylating agent Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-10-05
Discover the world’s best science and medicine | Nature.com
-
SUMOylation inhibitor activates immune response Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-10-05
Discover the world’s best science and medicine | Nature.com
-
Dual-targeting CAR-T cells in neuroblastoma Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-10-05
Discover the world’s best science and medicine | Nature.com
-
Exploring new frontiers in multiple sclerosis Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-10-05
Discover the world’s best science and medicine | Nature.com
-
Merck & Co. to buy Acceleron and its TGF-β ligand traps Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-10-04
Discover the world’s best science and medicine | Nature.com
-
Novel excipient review programme aims to bolster formulation innovation Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-10-04
Discover the world’s best science and medicine | Nature.com
-
First-in-class tissue factor-targeted antibody–drug conjugate secures FDA approval Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-10-04
Discover the world’s best science and medicine | Nature.com
-
FDA approves first EGFR exon 20 targeted kinase inhibitor Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-10-04
Discover the world’s best science and medicine | Nature.com
-
Publisher Correction: Evolution of the market for mRNA technology. Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-10-04 Wen Xie,Baiping Chen,John Wong
-
Gene therapy community grapples with toxicity issues, as pipeline matures Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-10-01
Cancer, hepatotoxicity, haematological and neurotoxicity concerns cause experts to call for more transparency and better manufacturing standards for AAV-based candidates.
-
Scooping up all the drugs Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-09-29
Discover the world’s best science and medicine | Nature.com
-
Allosteric adenosine receptor modulator alleviates pain Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-09-24
Discover the world’s best science and medicine | Nature.com
-
A novel single-agent antibiotic Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-09-23
Discover the world’s best science and medicine | Nature.com
-
Emerging therapeutic opportunities for integrin inhibitors Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-09-17 R. J. Slack, S. J. F. Macdonald, J. A. Roper, R. G. Jenkins, R. J. D. Hatley
Integrins are cell adhesion and signalling proteins crucial to a wide range of biological functions. Effective marketed treatments have successfully targeted integrins αIIbβ3, α4β7/α4β1 and αLβ2 for cardiovascular diseases, inflammatory bowel disease/multiple sclerosis and dry eye disease, respectively. Yet, clinical development of others, notably within the RGD-binding subfamily of αv integrins, including
-
Advances in TRP channel drug discovery: from target validation to clinical studies Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-09-15 Ari-Pekka Koivisto, Maria G. Belvisi, Rachelle Gaudet, Arpad Szallasi
Transient receptor potential (TRP) channels are multifunctional signalling molecules with many roles in sensory perception and cellular physiology. Therefore, it is not surprising that TRP channels have been implicated in numerous diseases, including hereditary disorders caused by defects in genes encoding TRP channels (TRP channelopathies). Most TRP channels are located at the cell surface, which
-
What does AlphaFold mean for drug discovery? Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-09-14
AlphaFold and RoseTTAFold have delivered a revolutionary advance for protein structure predictions, but the implications for drug discovery are more incremental. For now.
-
Upcoming market catalysts in Q4 2021 Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-09-13
Discover the world’s best science and medicine | Nature.com
-
The Nobel Prize-winning path from oxygen sensing research to new drugs Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-09-10
William Kaelin, a professor at the Dana-Farber Cancer Institute, discusses how his research into the mechanisms of oxygen sensing paved the way for two new drugs, and how to improve the calibre of preclinical research.
-
PIKfyve: a lipid kinase target for COVID-19, cancer and neurodegenerative disorders Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-09-09
Discover the world’s best science and medicine | Nature.com
-
Pfizer buys Trillium and its CD47 candidates for US$2.3 billion Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-09-06
Discover the world’s best science and medicine | Nature.com
-
Monoclonal antibodies show promise in phase I malaria trial Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-09-06
Discover the world’s best science and medicine | Nature.com
-
FDA releases proposed terms of PDUFA VII agreement Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-09-06
Discover the world’s best science and medicine | Nature.com
-
Pfizer’s COVID-19 vaccine secures first full FDA approval Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-09-06
Discover the world’s best science and medicine | Nature.com
-
Putting a PIN in pancreatic cancer Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-09-03
Discover the world’s best science and medicine | Nature.com
-
Overcoming ICB resistance in lung cancer Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-09-02
Discover the world’s best science and medicine | Nature.com
-
Nonhormonal target for endometriosis Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-09-02
Discover the world’s best science and medicine | Nature.com
-
Prime editing rescues mice from genetic disorders Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-09-02
Discover the world’s best science and medicine | Nature.com
-
Crossing the blood–brain barrier Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-09-02
Discover the world’s best science and medicine | Nature.com
-
Promoting APRIL interaction to control atherosclerosis Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-09-02
Discover the world’s best science and medicine | Nature.com
-
Evolution of the market for mRNA technology Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-09-02
Discover the world’s best science and medicine | Nature.com
-
Author Correction: Trends in kinase drug discovery: targets, indications and inhibitor design. Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-10-01 Misty M Attwood,Doriano Fabbro,Aleksandr V Sokolov,Stefan Knapp,Helgi B Schiöth
-
Tres Cantos Open Lab: celebrating a decade of innovation in collaboration to combat endemic infectious diseases Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-09-01 Felix Calderón, Lluis Ballell, David Barros, Graeme Bilbe, Nicholas Cammack, Raquel Gabarró, Audra Halsey, Penny M. Heaton, Gagandeep Kang, Valerie Mizrahi, Mike E. Strange, Pauline M. Williams, Elizabeth A. Winzeler, Alan H. Fairlamb
Tres Cantos Open Lab is a collaborative initiative that integrates teams from academia and GlaxoSmithKline to enable rapid testing of innovative therapeutic hypotheses for endemic infectious diseases. Here, we provide an overview of the key scientific achievements in its first decade.
-
Author Correction: PI3K inhibitors are finally coming of age. Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-10-01 Bart Vanhaesebroeck,Matthew W D Perry,Jennifer R Brown,Fabrice André,Klaus Okkenhaug
-
Hitting SEND on mRNA delivery Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-08-27
Discover the world’s best science and medicine | Nature.com
-
mRNA vaccines for infectious diseases: principles, delivery and clinical translation Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-08-25 Namit Chaudhary, Drew Weissman, Kathryn A. Whitehead
Over the past several decades, messenger RNA (mRNA) vaccines have progressed from a scepticism-inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the most rapid vaccine development in history, with mRNA vaccines at the forefront of those efforts. Although it is now clear that mRNA vaccines can rapidly and safely protect patients from infectious disease, additional research
-
Noncoding RNA mimic treats metabolic disorder Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-08-25 Crunkhorn, Sarah
Discover the world’s best science and medicine | Nature.com
-
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-08-20 Bieber, Thomas
Atopic dermatitis (AD) is a common chronic inflammatory skin disease with a complex pathophysiology that underlies a wide spectrum of clinical phenotypes. AD remains challenging to treat owing to the limited response to available therapies. However, recent advances in understanding of disease mechanisms have led to the discovery of novel potential therapeutic targets and drug candidates. In addition
-
What’s next for an immuno-oncology powerhouse? Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-08-13 Mullard, Asher
Dean Li, the recently appointed President of Merck Research Laboratories, discusses his immuno-oncology ambitions, emerging antiviral opportunities and the changing pace of technological cycle times.
-
Engineering islets from stem cells for advanced therapies of diabetes Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-08-10 Siehler, Johanna, Blöchinger, Anna Karolina, Meier, Matthias, Lickert, Heiko
Diabetes mellitus is a metabolic disorder that affects more than 460 million people worldwide. Type 1 diabetes (T1D) is caused by autoimmune destruction of β-cells, whereas type 2 diabetes (T2D) is caused by a hostile metabolic environment that leads to β-cell exhaustion and dysfunction. Currently, first-line medications treat the symptomatic insulin resistance and hyperglycaemia, but do not prevent
-
FDA approves first all-oral sleeping sickness drug Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-08-06 Mullard, Asher
Discover the world’s best science and medicine | Nature.com
-
FDA approves AstraZeneca’s anifrolumab for lupus Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-08-06 Mullard, Asher
Discover the world’s best science and medicine | Nature.com
-
Failure of Seres’s phase II ulcerative colitis programme renews microbiome concerns Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-08-06 Mullard, Asher
Discover the world’s best science and medicine | Nature.com
-
T cell-regulating therapies for autoimmune diseases take FDA rejection in stride Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-08-06 Cully, Megan
Despite a regulatory setback for Provention Bio’s diabetes prevention candidate teplizumab, hopes remain high for T cell-regulating therapies in autoimmune indications including multiple sclerosis, systemic lupus erythematosus and coeliac disease.
-
Antibiotics switch to anticancer target Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-08-05 Kingwell, Katie
Discover the world’s best science and medicine | Nature.com
-
Trends in kinase drug discovery: targets, indications and inhibitor design Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-08-05 Attwood, Misty M., Fabbro, Doriano, Sokolov, Aleksandr V., Knapp, Stefan, Schiöth, Helgi B.
The FDA approval of imatinib in 2001 was a breakthrough in molecularly targeted cancer therapy and heralded the emergence of kinase inhibitors as a key drug class in the oncology area and beyond. Twenty years on, this article analyses the landscape of approved and investigational therapies that target kinases and trends within it, including the most popular targets of kinase inhibitors and their expanding
-
UPR activator eliminates breast tumours Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-08-03 Crunkhorn, Sarah
Discover the world’s best science and medicine | Nature.com
-
Preventing hearing loss in neurofibromatosis Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-08-03 Crunkhorn, Sarah
Discover the world’s best science and medicine | Nature.com
-
Switch system fine tunes protein translation Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-08-03 Crunkhorn, Sarah
Discover the world’s best science and medicine | Nature.com
-
Understanding NMDA-mediated ketamine activity Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-08-03 Crunkhorn, Sarah
Discover the world’s best science and medicine | Nature.com
-
Kinase inhibitor combination combats liver cancer Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-08-03 Crunkhorn, Sarah
Discover the world’s best science and medicine | Nature.com
-
Therapeutic genome editing: regulatory horizons Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-07-29 Hines, Philip A., Agricola, Eleonora, Llinares Garcia, Jordi, O’Dwyer, Laurence , Herold, Ralf
An increasing number of genome-editing technologies are being developed. Here, we highlight some of the key issues for future therapies using these technologies from a regulatory perspective.
-
Targeting viruses in their phase Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-07-27 Strzyz, Paulina
Discover the world’s best science and medicine | Nature.com
-
Broadly neutralizing anti-coronavirus antibodies Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-07-27 Megan Cully
Discover the world’s best science and medicine | Nature.com
-
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2021-07-27 Ryan J. Sullivan, Jeffrey S. Weber
The immune-related adverse events associated with treatment with immune checkpoint inhibitors result in significant morbidity for patients as well as considerable cost to the health-care system, and can limit the use of these beneficial drugs. Understanding the mechanisms of these side effects and how they can be separated from the antitumour effects of immune checkpoint inhibitors, as well as identifying
京公网安备 11010802027423号